Iaso Bio's Ixazomib Injection (CT103A) Single-Cell Multi-Omics Study in CNS Autoimmune Diseases Published in Science Immunology

The principal investigator of this clinical study, Professor Wang Wei from Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologySaid, "As innovative clinical research on CAR-T therapy for autoimmune diseases continues to emerge in different countries and regions around the world, global experts are increasingly valuing and recognizing the promising application of this novel cell therapy for patients with relapsed and refractory immune disorders. Our current study is the world's first to conduct a deep single-cell multi-omics analysis of various body fluids from NMOSD patients, depicting the dynamic evolution of CAR-T cells within immune disease patients at the cellular and molecular levels. Particularly, we discovered that CAR-T cells with chemotactic properties are more likely to penetrate the blood-brain barrier and enter the central nervous system, directly targeting and eliminating abnormal immune cells there—a key finding for treating immune abnormalities in the central nervous system. Additionally, by comparing CAR-T cells in autoimmune patients with those in cancer patients, we identified several distinct characteristics of CAR-T cells in autoimmune patients, which could provide important scientific evidence for subsequent product iterations and improvements in CAR-T cell therapy for immune disorders."

Ms. Jin Hua Zhang, Founder and Chief Executive Officer of IASO Bio"It is with great pleasure that we announce the publication of another research achievement on the use of Equecabtagene Autoleucel Injection for treating autoimmune diseases in 'Science Immunology.' This marks the third academic article in the autoimmune field published in an international authoritative journal this year through the collaboration between IASO Bio and Professor Wang Wei's team from Wuhan Tongji Hospital. Once again, this research has achieved a 'world-first,' further validating the efficacy, safety, and durability of CAR-T therapy for treating autoimmune diseases. It has also reinforced IASO Bio’s commitment to focusing on the development of CAR-T products for autoimmune conditions. Currently, IASO Bio has received clinical approvals in China and the United States for autoimmune diseases such as neuromyelitis optica and myasthenia gravis, and plans to accelerate the progress of these projects. In terms of business development (BD) collaborations, in 2022, we entered into a global exclusive licensing agreement with Cabaletta Bio, a U.S.-based cell therapy company. We granted Cabaletta the exclusive global rights to develop, manufacture, and commercialize a clinically validated fully human CD19 sequence for CAR-T applications in autoimmune diseases. Currently, this product has received IND approval for multiple autoimmune indications including systemic lupus erythematosus/lupus nephritis, idiopathic inflammatory myopathy, systemic sclerosis, and myasthenia gravis, and its clinical trials are proceeding steadily. We will actively seek more global BD collaborations in the autoimmune space to expedite product development, ensuring that patients worldwide can access safer and more effective treatments sooner."

E.N.D